MK-677: 68 published COA source records
55 studies on MK-677 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 68 published MK-677 COA source records from third-party laboratories, covering 31 publicly attributable vendor identities. Across 15 records with positive numeric purity, the arithmetic mean is 98.6%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 5 records report measured amount more than 10% below the label. The latest recorded test date is 2026-09-18. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
MK-677: published third-party laboratory evidence
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-09-18. Aggregate calculated: 2026-10-18T15:38:52.437796+00:00. Calculation time is not a laboratory observation date.
Within that total, 26 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Top 3 vendor evidence profiles for MK-677
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 4 | 99.68% | 0 of 2 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #2 | 2 | 99.65% | 0 of 2 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #111477 · #111476 · #109314 · #109313 · #109162 · #109161
MK-677 studies and clinical research
-
Growth Hormone and IGF-1 axis implicated in brain regeneration across dementia, TBI, and stroke
If the systematic review confirms significant neuroregenerative potential for Growth Hormone (GH) and the `GH-IGF-1` axis, it could **redefine therapeutic strategies for devastating neurological conditions** like **de…
-
MK-0677 Trial Explores Potential for Alzheimer's Disease Treatment
Alzheimer's Disease remains a significant unmet medical need, and exploring novel therapeutic avenues is crucial. MK-0677, known as a growth hormone secretagogue (a compound that stimulates the secretion of growth hor…
-
Early Trial of MK0677 for Sarcopenia After Hip Fracture Terminated
-
Oral MK-677 Explored for Body Composition and Function in Older Adults
The potential for an oral GH secretagogue like MK-677 to restore youthful GH and IGF-I levels in older adults holds significant promise for combating age-related decline. If successful, this intervention could improve…
-
Ibutamoren Pilot Study Investigates Impact on Nonalcoholic Fatty Liver Disease
The prevalence of NAFLD and NASH is alarmingly high, and effective pharmacological treatments are scarce, making the exploration of new therapies critical. Positive findings from this pilot study could position Ibutam…
-
MK-0677 Study on Lean Body Mass in Advanced Kidney Disease Withdrawn
The withdrawal of this study means a significant opportunity was missed to explore a potential therapeutic avenue for muscle wasting in advanced CKD. Sarcopenia in CKD patients is a major predictor of morbidity and mo…
-
Oral MK-677 Boosts Growth Hormone, Lean Mass, and Metabolism in Obese Adults
-
Orally Active Growth Hormone Secretagogues: Current Status and Future Clinical Use
-
New Oral Peptidomimetics Potently Stimulate Growth Hormone Release
The discovery of potent, orally active Growth Hormone (GH) secretagogues like compound 18 is highly significant because it offers a non-invasive alternative to injectable peptide-based therapies. Such compounds could …
-
New Spiropiperidine Compounds Show Potent Growth Hormone Secretagogue Activity
The discovery of spiro(3H-1-benzopyran-2,3-piperidine), exhibiting low nanomolar potency, represents a significant breakthrough in the ongoing search for novel growth hormone secretagogues. This compound's high activi…
-
MK-0677 raises IGF-I and cortisol only via intact pituitary, not direct organ action
**MK-0677's entire hormonal efficacy — both IGF-I elevation and cortisol rise — is pituitary-gated**, meaning any context that compromises hypothalamic-pituitary function (severe illness, pituitary adenoma, prior radi…
-
C-Terminal Modifications Boost Potency of Growth Hormone Secretagogue NN703
This research highlights the significant potential of structural modifications to enhance the pharmacological profile of existing GHS. Identifying more potent analogues like NN703-S12 could lead to the development of …
-
MK-677 reduced LDL-C/HDL-C ratio in obese men but left Lp(a) unchanged
**The sustained reduction in the LDL-C/HDL-C ratio** is clinically meaningful because this ratio is an independent predictor of cardiovascular events, and oral GH secretagogues are already being explored for body comp…
-
MK-677 oral dosing raised bone turnover markers up to 29% in elderly adults
**Oral MK-677 produced measurable increases in both bone formation and resorption markers**, suggesting coupled bone remodeling rather than isolated catabolism — a more favorable skeletal profile than pure resorption-…
-
MK-677 transiently raised leptin and leptin/fat ratio in obese men over 8 weeks
**Clinicians and advanced users should note the transient nature of leptin elevation** — an effect that normalizes by 8 weeks — which suggests early adaptation in the `leptin` signaling axis and argues against long-te…
-
MK-0677 reversed age-related GH amplitude decline and GHS-R conserved 400 million years
**The existence of a deeply conserved GHS-R strongly supports the eventual identification of an endogenous ghrelin-axis ligand**, providing a rational pharmacological target for reversing age-related GH decline. For c…
-
Growth Hormone Secretagogues Drive GH, PRL, and ACTH Release via Distinct Age- and Gender-Dependent Mechanisms
**Clinicians and peptide users combining GHS with GHRH analogs** (e.g., sermorelin or CJC-1295) should note the synergistic GH release depends entirely on hypothalamo-pituitary integrity — individuals with hypothalami…
-
Growth Hormone Secretagogues Show Diverse Effects Across Multiple Organ Systems
This comprehensive review underscores the broad therapeutic potential of GHS across multiple organ systems and conditions. The observed benefits, from cardioprotection and growth promotion to metabolic improvements an…
-
Advanced Chromatography Developed to Separate Novel Growth Hormone Secretagogue Compounds
This research provides crucial analytical and preparative separation techniques essential for the development of new growth hormone secretagogue drugs. By enabling the purification of individual diastereomers, it allo…
-
Uncovering Key Drug Opportunities to Combat Aging and Neurodegenerative Diseases
This review was crucial in its time for mapping out nascent drug development pathways, providing a roadmap for future research. The identification of targets like growth hormone secretagogue receptor agonists and Nurr…
-
Adenosine Acts as a GHS-R Agonist, Binding the Same Receptor as MK-0677
**Adenosine — an endogenous purine nucleoside — is now a demonstrated `GHS-R` agonist**, fundamentally reshaping the view of what constitutes a natural GHS-R ligand and suggesting that purinergic signalling intersects…
-
GH Secretagogues Like MK-677 May Counter Sarcopenia by Restoring Pulsatile GH Secretion in Aging
**GH secretagogues represent a potentially superior alternative to exogenous GH** for older adults or clinicians pursuing somatotropic support, because they work through the body's own pulse-generation machinery rathe…
-
Adenosine Discovered as Natural Regulator of Growth Hormone Receptor
The study successfully identified adenosine as a partial agonist of the GHS-R, meaning it can activate the receptor but not to its full potential. Activation of GHS-R by adenosine was significantly inhibited by select…
-
MK-677 plus alendronate boosted femoral neck BMD 4.2% vs 2.5% with alendronate alone in postmenopausal women
**Femoral neck fracture is among the most clinically consequential osteoporotic injuries**, making even a modest site-specific BMD advantage potentially meaningful for fracture prevention — the combination's **+1.7 pe…
-
Ghrelin Receptors Found in Breast Cancer, May Inhibit Tumor Growth
-
Growth Hormone and Secretagogues: Impact on Bone Health Explored
This review underscores the critical role of the GH/IGF-1 axis in maintaining bone health and highlights the therapeutic potential of both GH and GHSs for bone disorders. The development of GHSs, which stimulate the b…
-
Oral Ibutamoren Effectively Boosts Growth Hormone in Deficient Children
-
Novel Small Molecules Mimic Ghrelin to Potently Activate Growth Hormone Receptor
-
SM-130686 orally increased fat-free mass and IGF-I in rats via GHS receptor
**Oral bioavailability combined with significant anabolic output** positions SM-130686 in the same practical niche as MK-677 but with a structurally novel scaffold — potentially relevant for researchers seeking altern…
-
Novel Oxindole Derivative Potently Stimulates Growth Hormone, Shows Oral Activity
The identification of SM-130686 (37S) represents a significant step forward, as it is an orally active, highly potent growth hormone secretagogue with a favorable pharmacokinetic profile in rats. Its ability to induce…
-
Ghrelin and Des-Acyl Ghrelin Protect Heart Cells from Death
-
Ghrelin: A Multifaceted Peptide Beyond Just Growth Hormone Regulation
This comprehensive review highlights ghrelin's multifaceted nature, demonstrating it is far more than just a GH secretagogue. Understanding ghrelin's broad actions opens new avenues for therapeutic development and dru…
-
Capromorelin: A Novel Oral Growth Hormone Secretagogue for Musculoskeletal Frailty
The discovery of capromorelin represents a significant advancement in the development of orally active Growth Hormone Secretagogues (GHSs). Its excellent bioavailability and oral activity directly address a major hurd…
-
MK-677 alters GH isoform proportions acutely but stabilizes after repeated dosing
**Practitioners and clinicians using MK-677 can be reassured** that the isoform composition of secreted GH — while transiently shifted on the first dose — stabilizes within 2 weeks of daily dosing. This means the **GH…
-
MK-0677 Raised IGF-1 by 84% in Hip-Fracture Patients But Failed to Improve Function
**The 84% IGF-1 elevation confirms MK-0677 reliably engages its target even in elderly, post-surgical patients** — a pharmacokinetically important signal for clinicians and researchers designing GH-axis interventions.…
-
MK-0677 Impurity Profile Tracked via RP-HPLC, LC-MS, and NMR Across Drug Development Stages
**Rigorous impurity tracking for MK-0677 and similar growth hormone secretagogues is directly relevant to product safety and batch-to-batch consistency**, whether in clinical trial supply or commercial manufacture. Fo…
-
New Compounds Boost Growth Hormone Release with High Potency
This discovery of highly potent GHSs like compound 8 holds significant therapeutic potential for a range of conditions. Such compounds could be invaluable for treating growth hormone deficiency, combating sarcopenia (…
-
Ghrelin and MK-0677 restore GH amplitude, liver phenotype, and dopamine signaling in aging
**GHS-R1a agonists may represent a single-class intervention capable of addressing GH decline, metabolic liver aging, immune senescence, and dopaminergic deficits simultaneously** — a breadth no current approved thera…
-
Growth Hormone and IGF-I Axis: A Key Player in Alzheimer's Disease?
This synthesis highlights the GH/IGF-I axis as a critical endocrine regulator in Alzheimer's disease, offering a novel perspective on its pathogenesis. Understanding this intricate relationship could pave the way for …
-
Novel Chemical Reaction Efficiently Builds Complex Drug-Like Spirocyclic Piperidines
-
New Growth Hormone Secretagogues Show Enhanced Potency and Efficacy
This research demonstrates a successful strategy for enhancing the potency and efficacy of growth hormone secretagogues through targeted structural modification. The improved in vivo efficacy and pharmacokinetic profi…
-
MK-677, Ghrelin, and GHRP-6 Share Overlapping TM-III/TM-VI Binding Site on GHSR
**Identifying a shared TM-III/TM-VI hotspot across peptide and nonpeptide GHSR agonists** means that medicinal chemistry efforts can converge on this core cleft rather than treating each chemotype as starting from scr…
-
MK-677 Raised IGF-1 to Youthful Levels and Increased Fat-Free Mass in Older Adults
**Oral MK-677 at 25 mg/day demonstrably attenuates age-related lean mass loss** and restores `IGF-1` to youthful concentrations, establishing proof-of-concept that `GHSR` agonism can counter one measurable dimension o…
-
New Therapies for Somatopause: Addressing Age-Related Growth Hormone Decline
This review underscores the critical need for more robust, evidence-based interventions to address somatopause and its associated age-related conditions. The findings highlight that current GH therapy, despite its pop…
-
MK-0677 raises IGF-1 but fails functional recovery and signals heart failure risk in hip fracture patients
**Elevated IGF-1 alone does not translate to clinically meaningful functional recovery** in frail elderly hip fracture patients — a finding that should temper enthusiasm for `GHSR` agonists in this population. The eme…
-
Oral ghrelin agonist MK-0677 increased serum IGF-1 by 65% in hemodialysis patients
This study establishes that MK-0677 is effective at raising IGF-1 levels in the specific, vulnerable population of hemodialysis patients, a group where anabolic support is critically needed to combat protein-energy wa…
-
MK-0677, a Ghrelin Agonist, Reduces Aβ Burden and Neuroinflammation in 5XFAD Alzheimer's Disease Mice
These findings suggest that activating the ghrelin receptor system via a compound like MK-0677 could be a viable therapeutic strategy for the early stages of Alzheimer's disease. By targeting multiple pathological fro…
-
Chronic MK-677 fails to promote growth in rats despite initial GH spike, desensitizing over time
These findings highlight a significant challenge for the long-term use of oral GHSs like MK-677 for growth promotion. While the compound can acutely stimulate a robust GH pulse, the body appears to develop a powerful …
-
MK0677 Boosts New Brain Cell Growth but Fails to Halt Damage in Alzheimer's Mice
-
MK-677 Supplement Linked to Reversible Liver Damage in Healthy Man
This case report highlights a critical, under-recognized risk associated with MK-677 use, particularly given its widespread availability and popularity in the performance-enhancing supplement market. It underscores th…
Research tools
Free, no account — handy when you're working with MK-677.
